Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Molecular mechanisms that confer antibacterial drug resistance

Abstract

Antibiotics — compounds that are literally ‘against life’ — are typically antibacterial drugs, interfering with some structure or process that is essential to bacterial growth or survival without harm to the eukaryotic host harbouring the infecting bacteria. We live in an era when antibiotic resistance has spread at an alarming rate1,2,3,4 and when dire predictions concerning the lack of effective antibacterial drugs occur with increasing frequency. In this context it is apposite to ask a few simple questions about these life-saving molecules. What are antibiotics? Where do they come from? How do they work? Why do they stop being effective? How do we find new antibiotics? And can we slow down the development of antibiotic-resistant superbugs?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Blockade of transpeptidation and transglycosylation steps of cell-wall biosynthesis by penicillins and vancomycins.
Figure 2: Structural and functional diversity of antibacterial drugs.
Figure 3: Principal resistance strategies for bacterial survival.
Figure 4: Counter-survival strategies.

References

  1. Neu, H.C. The crisis in antibiotic resistance. Science 257, 1064–1073 (1992).

    ADS  CAS  PubMed  Article  Google Scholar 

  2. Gold, H. S. & Moellering, R.C. Antimicrobial-drug resistance . N. Engl. J. Med. 335, 144– 1453 (1996).

    Google Scholar 

  3. Levy, S.B. The challenge of antibiotic resistance. Sci. Am. 275 , 46–53 (1998).

    Article  Google Scholar 

  4. Levy, S.B. Multidrug resistance—a sign of the times. N. Engl. J. Med. 338, 1376–1378 ( 1998).

    CAS  PubMed  Article  Google Scholar 

  5. Spratt, B. G. & Cromie, K. D. Rev. Infect. Dis. 10, 699 (1988).

    CAS  PubMed  Article  Google Scholar 

  6. Williams, D.H. The glycopeptide story—how to kill the deadly “superbugs” . Nat. Prod. Rep. 13, 469– 477 (1996).

    CAS  PubMed  Article  Google Scholar 

  7. Brisson-Noel, A., Trieu-Cuot, P. & Courvalin, P. Mechanism of action of spiramycin and other macrolides . J. Antimicrob. Chemother. 22(Suppl. B), 13–23 (1988).

    CAS  PubMed  Article  Google Scholar 

  8. Chopra, I. in The Tetracyclines, Handbook of Experimental Pharmacology Vol 78 (eds Hlavaka, J. J. & Boothe, J. H.) 317– 392 (Springer, Berlin, 1985).

    Google Scholar 

  9. Fourmy, D., Recht, M. I., Blanchard, S. C. & Puglisi, J.D. Structure of the A site of the Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274, 1371–1376 (1996).

    ADS  Article  Google Scholar 

  10. Kloss, P., Xiong, L., Shinabarger, D. L. & Mankin, A.S. Resistance of mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center . J. Mol. Biol. 294, 93– 101 (1999).

    CAS  PubMed  Article  Google Scholar 

  11. Shen, L.L. in Quinolone Antibacterial Agents, 2nd edn (eds Hooper, D. C. & Wolfson, J. S.) 77 (American Society for Microbiology, Washington DC, 1993).

    Google Scholar 

  12. Maxwell, A. DNA gyrase as a drug target. Trends Microbiol. 5, 102–109 (1997).

    CAS  PubMed  Article  Google Scholar 

  13. Ferrero, L., Cameron, B. & Crouzet, J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutant of Staphylococcus aureus . Antimicrob. Agents Chemother. 39, 1554–1558 (1995).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. Davies, J. Bacteria on the rampage. Nature 383, 219 –220 (1996).

    ADS  CAS  PubMed  Article  Google Scholar 

  15. Murray, E. Vancomycin resistant enterococci. Am. J. Med. 102, 284–293 (1997).

    CAS  PubMed  Article  Google Scholar 

  16. Arthur, M. & Courvalin, P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37, 1563–1571 (1993).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. Walsh, C, Fisher, S. L., Park, I. S., Prahalad, M. & Wu, Z. Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story. Chem. Biol. 3, 21–28 (1996 ).

    CAS  PubMed  Article  Google Scholar 

  18. Davies, J. Inactivation of antibiotics and the dissemination of resistance genes. Science 264, 375–382 ( 1994).

    ADS  CAS  PubMed  Article  Google Scholar 

  19. Schentag, J.J. et al. Genesis of methicillin resistant Staphylococcus aureus (MRSA). Clin. Infect. Dis. 26, 1204 –1212 (1998).

    CAS  PubMed  Article  Google Scholar 

  20. Jacoby, G. A. & Archer, G.L. New mechanisms of resistance to antibacterial agents. N. Engl. J. Med. 324, 601–612 (1991).

    CAS  PubMed  Article  Google Scholar 

  21. Levy, S.B. Active efflux mechanisms for antimicrobial resistance. Antimicrob. Agents Chemother. 36, 695–703 (1992).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. Paulsen, I. T., Brown, M. H. & Skurray, R.A. Proton-dependent multidrug efflux systems. Microbiol. Rev. 60, 575–608 (1996).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  23. Ross, J. et al. Inducible erythromycin resistance in staphylococci is encoded by a member of the ATP-binding transport super gene family. Mol. Microbiol. 4, 1207–1214 (1990).

    CAS  PubMed  Article  Google Scholar 

  24. Philippon, A., Labia, R. & Jacoby, G. Extended spectrum beta-lactamases. Antimicrob. Agents Chemother. 28, 302–307 (1985).

    Article  Google Scholar 

  25. Shaw, K. J., Rather, P. N., Hare, S. R. & Miller, G. H. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57, 138–163 (1993).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. Hon, W. C. et al. Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Cell 89, 887–895 ( 1997).

    CAS  PubMed  Article  Google Scholar 

  27. Bussiere, D. et al. Crystal structure of ErmC′, an rRNA methyltransferase which mediates antibiotic resistance in bacteria. Biochemistry 37, 7103–7112 ( 1998).

    CAS  PubMed  Article  Google Scholar 

  28. Bugg, T. D. H. et al. Molecular basis for vancomycin resistance in Enterococcus faecium, BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30, 10408–10415 (1991).

    CAS  PubMed  Article  Google Scholar 

  29. Song, M. D., Wachi, M., Doi, M., Ishino, F. & Matsuhashi, M. Evolution of an inducible penicillin target protein in MRSA by gene fusion. FEBS Lett. 221, 167 (1987).

    CAS  PubMed  Article  Google Scholar 

  30. Spratt, B. G. Resistance to antibiotics mediated by target alterations. Science 264, 388–393 ( 1994).

    ADS  CAS  PubMed  Article  Google Scholar 

  31. Knowles, J. R. Penicillin resistance: the chemistry of beta-lactamase inhibition. Acc. Chem. Res. 18, 97–105 (1985).

    CAS  Article  Google Scholar 

  32. The choice of antibacterial drugs. Med. Lett. 41, 95–104 ( 1999).

  33. Nelson, M. L., Park, B. H. & Levy, S. B. Molecular requirement for the inhibition of the tetracycline antiport protein and the effect of potent inhibitors on the growth of tetracycline-resistant bacteria. J. Med. Chem. 37, 1355– 1361 (1994).

    CAS  PubMed  Article  Google Scholar 

  34. Chu, D. W., Plattner, J. J. & Katz, L. New directions in antibacterial research. J. Med. Chem. 39, 3853–3874 (1996).

    CAS  PubMed  Article  Google Scholar 

  35. Agouridas, C., Benedetti, Y., Denis, A., Le Martert, O. & Chantot, J. F. Ketolides: a new distinct class of macrolide antibacterials, synthesis and structural characteristics of RU 004. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy Abstr. F158 (American Society for Microbiology, 1995).

  36. Biavasco, F. et al. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob. Agents Chemother. 41, 2165–2172 (1997).

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. Williams, D. H., Maguire, A. J., Tsuzuki, W. & Westwell, M. S. An analysis of the origins of cooperative binding energy of dimerization. Science 280, 711–713 ( 1998).

    ADS  CAS  PubMed  Article  Google Scholar 

  38. Ge, M. et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 284, 507–511 (1999).

    ADS  CAS  PubMed  Article  Google Scholar 

  39. Walsh, C. Deconstructing vancomycin. Science 284, 442–443 (1999).

    CAS  PubMed  Article  Google Scholar 

  40. Barry, A. L. & Fuchs, P. C. In vitro activities of a streptogramin (RP59500), three macrolides, and an azolide against four respiratory tract pathogens. Agents Chemother. 39, 238– 240 (1995).

    CAS  Article  Google Scholar 

  41. Linden, P. K., Pasculle, A. W., McDevitt, D. & Kramer, D. J. Effect of quinupristin/dalfopristin (synercid) treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF). J. Antimicrob. Chemother. 39(Suppl. A), 145 –151 (1997).

    CAS  PubMed  Article  Google Scholar 

  42. Chien, J. W., Kucia, M. L. & Salata, R. A. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin. Infect. Dis. 30, 146–151 (2000).

    CAS  PubMed  Article  Google Scholar 

  43. Kurz, M. & Guba, W. 3D structure of ramoplanin: a potent inhibitor of bacterial cell wall biosynthesis. Biochemistry 35, 12570–12575 (1996).

    CAS  PubMed  Article  Google Scholar 

  44. Chapra, I., Hodgson, J., Metcalf, B. & Poste, G. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob. Agents Chemother. 41, 497– 503 (1997).

    Article  Google Scholar 

  45. Chan, M. K. et al. Crystal structure of E. coli peptide deformylase. Biochemistry 36, 13904–13909 (1997).

    CAS  PubMed  Article  Google Scholar 

  46. Chen, D. Z. et al. Actinonin, a naturally occurring antibacterial agent is a potent peptide deformylase inhibitor. Biochemistry 39, 1256–1262 (2000).

    CAS  PubMed  Article  Google Scholar 

  47. Barret, J. F. & Isaacson, R. E. Bacterial virulence as a potential target for therapeutic intervention. Annu. Rep. Med. Chem. 30, 111–118 (1995).

    Google Scholar 

  48. Stephens, C. & Shapiro, L. Bacterial protein secretion—a target for new antibiotics? Chem. Biol. 4, 637–641 (1997).

    CAS  PubMed  Article  Google Scholar 

  49. Barret, J. F. & Hoch, J. A. Two-component signal transduction as a target for microbial anti-infective therapy. Antimicrob. Agents Chemother. 42, 1529–1536 (1998).

    Article  Google Scholar 

  50. Kleerebezem, M., Quadri, L. E. N., Kuipers, O. P. & de Vos, W. M. Quorum sensing by peptide pheromones and two-component signal-transduction systems in gram-positive bacteria. Mol. Microbiol. 24, 895–904 (1997).

    CAS  PubMed  Article  Google Scholar 

  51. Reimmann, C. et al. The global activator gacA of Pseudomonas aeruginosa PAO positively controls the production of the autoinducer N-butyryl-homoserine lactone and the formation of the virulence factors pyocyanin, cyanide, and lipase. Mol. Microbiol. 24, 309– 319 (1997).

    CAS  PubMed  Article  Google Scholar 

  52. Sofia, M. J. et al. Discovery of novel disaccharide antibacterial agents using a combinatorial library approach. J. Med. Chem. 42, 8194–8198 (1999).

    Article  CAS  Google Scholar 

  53. Tan, D. S., Foley, M. A., Shair, M. D. & Schreiber, S. L. Stereoselective synthesis of over two million compounds having structural features both reminiscent of natural products and compatible with miniaturized cell-based assays. J. Am. Chem. Soc. 120, 8565–8566 (1998).

    CAS  Article  Google Scholar 

  54. Leadlay, P. F. Combinatorial approaches to polyketide biosynthesis. Curr. Opin. Chem. Biol. 1, 162–168 ( 1997).

    CAS  PubMed  Article  Google Scholar 

  55. Katz, L. Manipulation of modular polyketide synthases. Chem. Rev. 97, 2557–2575 (1997).

    CAS  PubMed  Article  Google Scholar 

  56. Khosla, C. Harnessing the biosynthetic potential of modular polyketide synthases. Chem. Rev. 97, 2577–2590 (1997).

    CAS  PubMed  Article  Google Scholar 

  57. Cane, D. E., Walsh, C. T. & Khosla, C. Harnessing the biosynthetic code: combinations, permutations, and mutations. Science 282, 63– 68 (1998).

    CAS  PubMed  Article  Google Scholar 

  58. McDaniel, R. et al. Multiple genetic modifications of the erythromycin polyketide synthase to produce a library of novel "unnatural" natural products. Proc. Natl Acad. Sci. USA 96, 1846– 1851 (1999).

    ADS  CAS  PubMed  PubMed Central  Article  Google Scholar 

  59. Zhao, L. et al. Engineering a methymycin/pikromycin-calicheamicin hybrid: construction of two new macrolides carrying a designed sugar moiety. J. Am. Chem. Soc. 121, 9881–9882 (1999).

    CAS  Article  Google Scholar 

  60. Schlaes, D.M. et al. Guidelines for the prevention of antimicrobial resistance in hospitals. Clin. Infect. Dis. 25, 583 –599 (1997).

    Google Scholar 

  61. Waldvogel, F. A. New resistance in Staphylococcus aureus. N. Engl. J. Med. 340, 556–557 ( 1999).

    CAS  PubMed  Article  Google Scholar 

  62. Drugs for HIV infection. Med. Lett. 42, 1–6 (2000 ).

  63. Witte, W. Medical consequences of antibiotic use in agriculture. Science 279, 996–997 ( 1998).

    ADS  CAS  PubMed  Article  Google Scholar 

  64. Chow, J. W., Donahedian, S. M. & Zervos, M. J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin. Infect. Dis. 24, 90–91 ( 1997).

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgements

Experimental work cited in this review is supported by the National Institutes of Health. I thank R. Chen and I. Lessard for preparation of the artwork.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Walsh, C. Molecular mechanisms that confer antibacterial drug resistance. Nature 406, 775–781 (2000). https://doi.org/10.1038/35021219

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/35021219

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing